Income statement
USD
Annual
| Metric | 2003 | 2002 | 2001 |
|---|---|---|---|
| Revenue | 0 | 3M | 941K |
| Gross Profit | 0 | 3M | 941K |
| Operating Income | 863K | 2M | 2M |
| EBITDA | -863K | -2M | -1M |
| Net Income | -863K | -2M | -2M |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Spencer Pharmaceutical Inc. (SPPH) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +66.7%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +66.7%, free cash flow +71.3% with operating margin 0.0% and ROIC 21.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SPPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SPPH Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SPPH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$941.4K
-64.1% YoY
FY Net Income
-$2.2M
+0.6% YoY
Free Cash Flow
$114.4K
+104.3% YoY
Revenue Growth
-100.0%
EPS Growth
+66.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2003 | 2002 | 2001 |
|---|---|---|---|
| Revenue | 0 | 3M | 941K |
| Gross Profit | 0 | 3M | 941K |
| Operating Income | 863K | 2M | 2M |
| EBITDA | -863K | -2M | -1M |
| Net Income | -863K | -2M | -2M |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2003 | 2002 | 2001 |
|---|---|---|---|
| Cash & Equivalents | 21K | 304K | 1M |
| Total Assets | 4M | 419K | 2M |
| Total Liabilities | 380K | 839K | 2M |
| Shareholder Equity | 4M | -420K | 281K |
| Total Debt | 154K | 0 | 0 |
| Net Debt | 133K | -304K | -1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
146K
+105.5% YoY
Capital Expenditures
31K
-99.6% YoY
Free Cash Flow
114K
+104.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-50.2%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.